Press releases
2016
20 October, 2016
Interim report January - September 2016
25 August, 2016
Interim report January - June 2016
25 August, 2016
Interim report January - June 2016
16 May, 2016
New data strengthens claim that PledOx® does not negatively interfere with the anti-cancer effect of chemotherapy
29 April, 2016
Interim report first quarter 2016
29 February, 2016
Year end report 2015
2015
1 December, 2015
PLEDPHARMA PRESENTS NEW IN-DEPTH FOLLOW-UP DATA FROM PLIANT STUDY - PLEDOX® SHOWN TO REDUCE CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY BY 75 PERCENT
19 November, 2015
PLEDPHARMA REPORTS CONSTRUCTIVE MEETING WITH THE FDA AND PRESENTS NEW FOLLOW-UP DATA
20 October, 2015
Interim report third quarter 2015
22 September, 2015
KEY COMPOUND PATENT FOR PLEDOX® AND ALADOTE® SET TO GAIN US APPROVAL
18 August, 2015
Interim report second quarter 2015
26 June, 2015
PLEDPHARMA PRESENTS ADDITIONAL RESULTS FROM A PHASE IIB STUDY WITH PLEDOX® AT THE SCIENTIFIC CONFERENCE MASCC
21 April, 2015
Interim report first quarter 2015
17 February, 2015
Year-end report 2014
2014
17 December, 2014
PledPharma’s rights issue oversubscribed by 34 percent
14 November, 2014
More than 50 percent of the owners confirm subscription commitments in PledPharma’s planned rights issue
24 October, 2014
PledPharma AB - Interim report third quarter 2014
24 October, 2014
PledPharma presents a new project against acetaminophen-induced poisoning, aimed to be financed by a rights issue
12 September, 2014
Information video about PLIANT study available